The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

ClinicalTrials & Tribulations

San Antonio Breast Cancer Symposium 2022 tackled big obstacles, recommended solutions for breast cancer progress

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

To provide a roadmap for accelerating progress against breast cancer over the next 10 years, an expert panel was convened at the 2022 San Antonio Breast Cancer Symposium to identify the biggest obstacles hindering our ability to cure breast cancer and to propose transformative solutions to address these obstacles.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Angela DeMichele, MD, MSCE
Alan and Jill Miller Professor in Breast Cancer Excellence, Co-leader, Breast Cancer Research Program, Co-director, 2-PREVENT Breast Cancer Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania
Rajarshi Sengupta, PhD
Director, scientific research analysis and communication, American Association for Cancer Research
Carlos L. Arteaga, MD
Director, Harold C. Simmons Comprehensive Cancer Center, Associate dean of oncology programs, Lisa K. Simmons Distinguished Chair in Comprehensive Oncology, UT Southwestern Medical Center
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Fatty acids promote immune suppression and therapy resistance in triple negative breast cancer, Baylor Medicine study finds

A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.
In Brief

Tari King appointed chief surgical officer for cancer service line, co-director of Glenn Family Breast Center at Winship, chief of Division of Breast Surgery at Emory

Breast cancer surgeon Tari A. King was appointed as chief surgical officer for the cancer service line at Winship Cancer Institute of Emory University and Emory Healthcare. Joining Emory on July 14, she will also be the chief of the newly formed Division of Breast Surgery in the Department of Surgery at Emory University School of Medicine and co-director of Winship’s Glenn Family Breast Center.
Byline
Angela DeMichele, MD, MSCE
Alan and Jill Miller Professor in Breast Cancer Excellence, Co-leader, Breast Cancer Research Program, Co-director, 2-PREVENT Breast Cancer Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania
Rajarshi Sengupta, PhD
Director, scientific research analysis and communication, American Association for Cancer Research
Carlos L. Arteaga, MD
Director, Harold C. Simmons Comprehensive Cancer Center, Associate dean of oncology programs, Lisa K. Simmons Distinguished Chair in Comprehensive Oncology, UT Southwestern Medical Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account